0.8899
price down icon6.11%   -0.0579
after-market Handel nachbörslich: .85 -0.0399 -4.48%
loading
Schlusskurs vom Vortag:
$0.9478
Offen:
$0.9194
24-Stunden-Volumen:
299.57K
Relative Volume:
0.17
Marktkapitalisierung:
$4.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+11.32%
1M Leistung:
+21.90%
6M Leistung:
-89.63%
1J Leistung:
-99.36%
1-Tages-Spanne:
Value
$0.8747
$0.94
1-Wochen-Bereich:
Value
$0.82
$1.42
52-Wochen-Spanne:
Value
$0.5338
$147.00

Cero Therapeutics Holdings Inc Stock (CERO) Company Profile

Name
Firmenname
Cero Therapeutics Holdings Inc
Name
Telefon
650-407-2376
Name
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Name
Mitarbeiter
8
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
CERO's Discussions on Twitter

Vergleichen Sie CERO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
CERO
Cero Therapeutics Holdings Inc
0.8899 4.30M 0 0 0 0.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
509.50 126.59B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
598.76 64.27B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
645.14 36.31B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
263.24 31.32B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
104.15 27.60B 2.98B -717.57M -264.74M -2.9987

Cero Therapeutics Holdings Inc Aktie (CERO) Neueste Nachrichten

pulisher
Apr 30, 2025

CERo Therapeutics begins phase 1 trial for leukemia treatment - Investing.com Australia

Apr 30, 2025
pulisher
Apr 30, 2025

CERo Therapeutics Initiates Phase 1 Clinical Trial for CER-1236 at TriStar Centennial Medical Center to Treat Acute Myeloid Leukemia - Nasdaq

Apr 30, 2025
pulisher
Apr 30, 2025

Cero Therapeutics Announces Tristar Centennial Medical Center As A Clinical Trial Site For Its Phase 1 Clinical Trial Of Cer-1236 In Acute Myeloid Leukemia - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

CERo Therapeutics Holdings, Inc. Announces TriStar - GlobeNewswire

Apr 30, 2025
pulisher
Apr 30, 2025

Leading Cancer Center to Test Revolutionary AML Treatment: CERo's Novel T Cell Therapy Enters Clinical Trial - Stock Titan

Apr 30, 2025
pulisher
Apr 28, 2025

CERo Therapeutics Holdings Inc (CERO) Stock: A Year of Market Movement, Down and Up - investchronicle.com

Apr 28, 2025
pulisher
Apr 28, 2025

CERo Therapeutics announces up to $8M Series D financing; shares up - MSN

Apr 28, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc [CERO] is -81.50% lower this YTD. Is it still time to buy? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

Market cap of Crown LNG Holdings Limited [CGBS] reaches 59.64M – now what? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

New Providence Acquisition Corp III [NPACU] Stock trading around $10.02 per share: What’s Next? - dbtnews.com

Apr 25, 2025
pulisher
Apr 25, 2025

A company insider recently sold 50,896 shares of OppFi Inc [OPFI]. Should You Sale? - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc [CERO] Records 50-Day SMA of $1.1308 - knoxdaily.com

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings, Inc. to Present Poster on Lead - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Breakthrough Leukemia Treatment: CERo's First-in-Human Trial Results Revealed at ASCO 2025 - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Holdings of CERo Therapeutics Holdings Inc (CERO) are aligned with the stars - Sete News

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics Holdings Inc’s Market Journey: Closing Strong at 1.11, Up 38.85 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

Market Momentum: Haoxin Holdings Ltd (HXHX) Registers a 16.47 Increase, Closing at 1.98 - DWinneX

Apr 25, 2025
pulisher
Apr 25, 2025

CERo Therapeutics (NASDAQ:CERO) Upgraded at D Boral Capital - Defense World

Apr 25, 2025
pulisher
Apr 24, 2025

CERo Therapeutics begins Phase 1 trial for AML treatment By Investing.com - Investing.com South Africa

Apr 24, 2025
pulisher
Apr 24, 2025

Gold Gains 1%; Bristol Myers Squibb Posts Upbeat Results - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Dow Jumps Over 200 Points; PepsiCo Cuts Earnings Outlook - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Holdings Inc (CERO)’s stock price range in the last year - uspostnews.com

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics begins Phase 1 trial for AML treatment - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon - GlobeNewswire

Apr 24, 2025
pulisher
Apr 24, 2025

Major Blood Cancer Center Joins CERo's Novel AML Treatment Trial, June Dosing Planned - Stock Titan

Apr 24, 2025
pulisher
Apr 23, 2025

CERo Therapeutics (NASDAQ:CERO) Coverage Initiated by Analysts at D. Boral Capital - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Boral Capital sets Cero Therapeutics stock with Buy rating - Investing.com Australia

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics secures $8 million in funding for cancer therapy By Investing.com - Investing.com South Africa

Apr 22, 2025
pulisher
Apr 22, 2025

What Are You Thinking About Investing In CERo Therapeutics Holdings Inc (NASDAQ: CERO) Stock? - Stocksregister

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Raises Up To $8 Mln To Advance T Cell Therapy Programs - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

D. Boral Capital Initiates Coverage of CERo Therapeutics Holdings (CERO) with Buy Recommendation - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

Boral Capital sets Cero Therapeutics stock with Buy rating By Investing.com - Investing.com Canada

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics secures $8 million in funding for cancer therapy - Investing.com

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Holdings, Inc. Announces $8 Million Securities Purchase Agreement to Advance Immunotherapy Development - Nasdaq

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing - GlobeNewswire

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Lands $8M Series D Funding: FDA-Cleared Cancer Trials at MD Anderson Set to Launch - Stock Titan

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Holdings, Inc. Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing - ADVFN

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236 - ADVFN

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Holdings, Inc. Presents Encouraging Preclinical Data Demonstrating CER-1236 May be Targeted to Ovarian Cancer Cells Without Toxicities at 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors Meeting - ADVFN

Apr 22, 2025
pulisher
Apr 22, 2025

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services - ADVFN

Apr 22, 2025
pulisher
Apr 16, 2025

Insider Sale Alert: CERo Therapeutics Holdings Inc [CERO] – Is it Time to sell? - knoxdaily.com

Apr 16, 2025
pulisher
Apr 15, 2025

CERO THERAPEUTICS HOLDINGS, INC. SEC 10-K Report - TradingView

Apr 15, 2025
pulisher
Apr 14, 2025

CERO stock plunges to 52-week low of $0.64 amid market challenges By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

CERO stock plunges to 52-week low of $0.64 amid market challenges - Investing.com Canada

Apr 14, 2025
pulisher
Apr 10, 2025

CERo Therapeutics expands patent portfolio for cancer therapy By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

CERo Therapeutics expands patent portfolio with new US approvals By Investing.com - Investing.com South Africa

Apr 10, 2025
pulisher
Apr 10, 2025

Cero Therapeutics Announces Critical Patent Application Allowances From The U.S. Patent Office - marketscreener.com

Apr 10, 2025
pulisher
Apr 10, 2025

CERo Therapeutics expands patent portfolio for cancer therapy - Investing.com Australia

Apr 10, 2025
pulisher
Apr 10, 2025

CERo Therapeutics expands patent portfolio with new US approvals - Investing.com

Apr 10, 2025
pulisher
Apr 10, 2025

CERo Therapeutics Holdings, Inc. Announces Critical Patent - GlobeNewswire

Apr 10, 2025
pulisher
Apr 10, 2025

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. - Bluefield Daily Telegraph

Apr 10, 2025

Finanzdaten der Cero Therapeutics Holdings Inc-Aktie (CERO)

Es liegen keine Finanzdaten für Cero Therapeutics Holdings Inc (CERO) vor. Überprüfen Sie andere Aktien für weitere Informationen.

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.15
price up icon 1.73%
$72.00
price up icon 0.84%
$32.82
price up icon 0.34%
$24.12
price up icon 2.12%
biotechnology ONC
$259.81
price up icon 4.02%
$104.15
price up icon 0.14%
Kapitalisierung:     |  Volumen (24h):